A multi-subunit Chlamydia vaccine inducing neutralizing antibodies and strong IFN-γ + CMI responses protects against a genital infection in minipigs

Immunology and Cell Biology

Volumn 94, Issue 2, 2016, Pages 185-195

  Bøje, Sarah ^a,b   Olsen, Anja Weinreich ^b   Erneholm, Karin ^a,b   Agerholm, Jørgen Steen ^a   Jungersen, Gregers ^c   Andersen, Peter ^b   Follmann, Frank ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b STATENS SERUM INSTITUT   (Denmark)

^c TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CAF01; CTH93 PROTEIN; GAMMA INTERFERON; HIREP1 PROTEIN; HYBRID PROTEIN; IMMUNOLOGICAL ADJUVANT; NEUTRALIZING ANTIBODY; OUTER MEMBRANE PROTEIN; SUBUNIT VACCINE; UNCLASSIFIED DRUG; BACTERIAL VACCINE; INACTIVATED VACCINE; MAJOR OUTER MEMBRANE PROTEIN, CHLAMYDIA PNEUMONIAE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG MIXTURE; FEMALE; GENITAL TRACT INFECTION; GOTTINGEN MINIPIG; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGENICITY; IN VITRO STUDY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; TH1 CELL; VACCINATION; ANIMAL; BLOOD; CHLAMYDIA; CHLAMYDIA INFECTIONS; DISEASE MODEL; GENETICS; IMMUNIZATION; IMMUNOLOGY; MINIPIG; PIG;

ANIMALS; ANTIBODIES, NEUTRALIZING; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; CHLAMYDIA; CHLAMYDIA INFECTIONS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION; INTERFERON-GAMMA; RECOMBINANT FUSION PROTEINS; SWINE; SWINE, MINIATURE; TH1 CELLS; VACCINES, INACTIVATED; VACCINES, SUBUNIT;

EID: 84983133947     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2015.79     Document Type: Article

References (51)

1. World Health Organization: Global incidence and prevalence of selected curable sexually transmitted infections-2008. World Health Organization, 2012. Report No.: 9789241503839.
2. Peipert JF. Clinical practice. Genital chlamydial infections. New Engl J Med 2003; 349: 2424-2430.
3. Gottlieb SL, Low N, Newman LM, Bolan G, Kamb M, Broutet N. Toward global prevention of sexually transmitted infections (STIs): the need for STI vaccines. Vaccine 2014; 32: 1527-1535.
4. Geisler WM, Lensing SY, Press CG, Hook EW 3rd. Spontaneous resolution of genital Chlamydia trachomatis infection in women and protection from reinfection. J Infect Dis 2013; 207: 1850-1856.
5. Brunham RC, Kuo CC, Cles L, Holmes KK. Correlation of host immune response with quantitative recovery of Chlamydia trachomatis from the human endocervix. Infect Immun 1983; 39: 1491-1494.
6. Cohen CR, Koochesfahani KM, Meier AS, Shen CX, Karunakaran K, Ondondo B et al. Immunoepidemiologic profile of Chlamydia trachomatis infection: Importance of heatshock protein 60 and interferon-gamma. J Infect Dis 2005; 192: 591-599.
7. Morrison RP, Caldwell HD. Immunity to murine chlamydial genital infection. Infect Immun 2002; 70: 2741-2751.
8. Morrison SG, Su H, Caldwell HD, Morrison RP. Immunity to murine Chlamydia trachomatis genital tract reinfection involves B cells and CD4(+) T cells but not CD8 (+) T cells. Infect Immun 2000; 68: 6979-6987.
9. Su H, Caldwell HD. CD4+ T cells play a significant role in adoptive immunity to Chlamydia trachomatis infection of the mouse genital tract. Infect Immun 1995; 63: 3302-3308.
10. Su H, Caldwell HD. Immunogenicity of a synthetic oligopeptide corresponding to antigenically common T-helper and B-cell neutralizing epitopes of the major outer membrane protein of Chlamydia trachomatis. Vaccine 1993; 11: 1159-1166.
11. Moore T, Ananaba GA, Bolier J, Bowers S, Belay T, Eko FO et al. Fc receptor regulation of protective immunity against Chlamydia trachomatis. Immunology 2002; 105: 213-221.
12. Nichols RL, Bell SD, Murray ES, Haddad NA, Bobb AA. Studies on trachoma: V. clinical observations in a field trial of bivalent trachoma vaccine at three dosage levels in Saudi Arabia. Am J Trop Med Hyg 1966; 15: 639-647.
13. Wang SP, Grayston JT, Alexander ER. Trachoma vaccine studies in monkeys. Am J ophthalmol 1967; 63 (Suppl): 1615-1630.
14. Grayston JT, Wang SP. The potential for vaccine against infection of the genital tract with Chlamydia trachomatis. Sex Transm Dis 1978; 5: 73-77.
15. Coler RN, Bhatia A, Maisonneuve JF, Probst P, Barth B, Ovendale P et al. Identification and characterization of novel recombinant vaccine antigens for immunization against genital Chlamydia trachomatis. FEMS Immunol Med Microbiol 2009; 55: 258-270.
16. Finco O, Frigimelica E, Buricchi F, Petracca R, Galli G, Faenzi E et al. Approach to discover T-and B-cell antigens of intracellular pathogens applied to the design of Chlamydia trachomatis vaccines. Proc Natl Acad Sci USA 2011; 108: 9969-9974.
17. Olsen AW, Andersen P, Follmann F. Characterization of protective immune responses promoted by human antigen targets in a urogenital Chlamydia trachomatis mouse model. Vaccine 2014; 32: 685-692.
18. Rockey DD, Wang J, Lei L, Zhong G. Chlamydia vaccine candidates and tools for chlamydial antigen discovery. Expert Rev Vaccines 2009; 8: 1365-1377.
19. Pal S, Theodor I, Peterson EM, de la Maza LM. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge. Infect Immun 2001; 69: 6240-6247.
20. Sun G, Pal S, Weiland J, Peterson EM, de la Maza LM. Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein. Vaccine 2009; 27: 5020-5025.
21. Igietseme JU, Eko FO, Black CM. Chlamydia vaccines: recent developments and the role of adjuvants in future formulations. Expert Rev Vaccines 2011; 10: 1585-1596.
22. Yu H, Jiang X, Shen C, Karunakaran KP, Jiang J, Rosin NL et al. Chlamydia muridarum T-cell antigens formulated with the adjuvant DDA/TDB induce immunity against infection that correlates with a high frequency of gamma interferon (IFN-gamma)/tumor necrosis factor alpha and IFN-gamma/interleukin-17 double-positive CD4+ T cells. Infect Immun 2010; 78: 2272-2282.
23. Karlsson I, Brandt L, Vinner L, Kromann I, Andreasen LV, Andersen P et al. Adjuvanted HLA-supertype restricted subdominant peptides induce new T-cell immunity during untreated HIV-1-infection. Clin Immunol 2013; 146: 120-130.
24. van Dissel JT, Joosten SA, Hoff ST, Soonawala D, Prins C, Hokey DA et al. A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosisspecific T-cell responses in human. Vaccine 2014; 32: 7098-7107.
25. Dawson H. A comparative assessment of the pig, mouse and human genomes: structural and functional analysis of genes involved in immunity and inflammation. In:McAnulty PAD AD, Ganderup NC, Hastings KL (eds). The Minipig In Biomedical Research. CRC Press: Taylor and Francis Group, Taylor and Francis Group, 2012; pp 323-342.
26. Fairbairn L, Kapetanovic R, Sester DP, Hume DA. The mononuclear phagocyte system of the pig as a model for understanding human innate immunity and disease. J Leukoc Biol 2011; 89: 855-871.
27. Meurens F, Summerfield A, Nauwynck H, Saif L, Gerdts V. The pig: a model for human infectious diseases. Trends Microbiol 2012; 20: 50-57.
28. Vanrompay D, Hoang TQ, De Vos L, Verminnen K, Harkinezhad T, Chiers K et al. Specific-pathogen-free pigs as an animal model for studying Chlamydia trachomatis genital infection. Infect Immun 2005; 73: 8317-8321.
29. Olsen AW, Follmann F, Erneholm K, Rosenkrands I, Andersen P. Vaccine promoted neutralizing antibodies directed to the VD4 of MOMP protect against Chlamydia trachomatis infection and upper genital tract pathology. J Infect Dis; e-pub ahead of print 6 March 2015.
30. Meoni E, Faenzi E, Frigimelica E, Zedda L, Skibinski D, Giovinazzi S et al. CT043, a protective antigen that induces a CD4+ Th1 response during Chlamydia trachomatis infection in mice and humans. Infect Immun 2009; 77: 4168-4176.
31. Follmann F, Olsen AW, Jensen KT, Hansen PR, Andersen P, Theisen M. Antigenic profiling of a Chlamydia trachomatis gene-expression library. J Infect Dis 2008; 197: 897-905.
32. Byrne GI, Stephens RS, Ada G, Caldwell HD, Su H, Morrison RP et al. Workshop on in vitro neutralization of Chlamydia trachomatis: summary of proceedings. J Infect Dis 1993; 168: 415-420.
33. Kari L, Bakios LE, Goheen MM, Bess LN, Watkins HS, Southern TR et al. Antibody signature of spontaneous clearance of Chlamydia trachomatis ocular infection and partial resistance against re-challenge in a nonhuman primate trachoma model. PLoS Negl Trop Dis 2013; 7: e2248.
34. Li W, Murthy AK, Guentzel MN, Chambers JP, Forsthuber TG, Seshu J et al. Immunization with a combination of integral chlamydial antigens and a defined secreted protein induces robust immunity against genital chlamydial challenge. Infect Immun 2010; 78: 3942-3949.
35. Tan C, Hsia RC, Shou H, Haggerty CL, Ness RB, Gaydos CA et al. Chlamydia trachomatis-infected patients display variable antibody profiles against the nine-member polymorphic membrane protein family. Infect Immun 2009; 77: 3218-3226.
36. Agger EM, Rosenkrands I, Hansen J, Brahimi K, Vandahl BS, Aagaard C et al. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PloS One 2008; 3: e3116.
37. Olsen AW, Follmann F, Jensen K, Hojrup P, Leah R, Sorensen H et al. Identification of CT521 as a frequent target of Th1 cells in patients with urogenital Chlamydia trachomatis infection. J Infect Dis 2006; 194: 1258-1266.
38. Ortiz L, Demick KP, Petersen JW, Polka M, Rudersdorf RA, Van der Pol B et al. Chlamydia trachomatis major outer membrane protein (MOMP) epitopes that activate HLA class II-restricted T cells from infected humans. J Immunol 1996; 157: 4554-4567.
39. Arno JN, Xie C, Jones RB, Van Der Pol B. Identification of T cells that respond to serovar-specific regions of the Chlamydia trachomatis major outer membrane protein in persons with serovar E infection. J Infect Dis 1998; 178: 1713-1718.
40. Karunakaran KP, Yu H, Jiang X, Chan Q, Moon KM, Foster LJ et al. Outer membrane proteins preferentially load MHC class II peptides: implications for a Chlamydia trachomatis T cell vaccine. Vaccine 2015; 33: 2159-2166.
41. Kim SK, DeMars R. Epitope clusters in the major outer membrane protein of Chlamydia trachomatis. Curr Opin Immunol 2001; 13: 429-436.
42. Ortiz L, Angevine M, Kim SK, Watkins D, DeMars R. T-cell epitopes in variable segments of Chlamydia trachomatis major outer membrane protein elicit serovarspecific immune responses in infected humans. Infect Immun 2000; 68: 1719-1723.
43. Peterson EM, Cheng X, Markoff BA, Fielder TJ, de la Maza LM. Functional and structural mapping of Chlamydia trachomatis species-specific major outer membrane protein epitopes by use of neutralizing monoclonal antibodies. Infect Immun 1991; 59: 4147-4153.
44. Kubo A, Stephens RS. Characterization and functional analysis of PorB, a Chlamydia porin and neutralizing target. Mol Microbiol 2000; 38: 772-780.
45. Kari L, Southern TR, Downey CJ, Watkins HS, Randall LB, Taylor LD et al. Chlamydia trachomatis polymorphic membrane protein D is a virulence factor involved in early host-cell interactions. Infect Immun 2014; 82: 2756-2762.
46. Kari L, Whitmire WM, Crane DD, Reveneau N, Carlson JH, Goheen MM et al. Chlamydia trachomatis native major outer membrane protein induces partial protection in nonhuman primates: implication for a trachoma transmission-blocking vaccine. J Immunol 2009; 182: 8063-8070.
47. Rey-Ladino J, Koochesfahani KM, Zaharik ML, Shen CX, Brunham RC. A live and inactivated Chlamydia trachomatis mouse pneumonitis strain induces the maturation of dendritic cells that are phenotypically and immunologically distinct. Infect Immun 2005; 73: 1568-1577.
48. Stephens RS, Kalman S, Lammel C, Fan J, Marathe R, Aravind L et al. Genome sequence of an obligate intracellular pathogen of humans: Chlamydia trachomatis. Science 1998; 282: 754-759.
49. Olsen AW, Follmann F, Hojrup P, Leah R, Sand C, Andersen P et al. Identification of human T cell targets recognized during Chlamydia trachomatis genital infection. J Infect Dis 2007; 196: 1546-1552.
50. Hansen J, Jensen KT, Follmann F, Agger EM, Theisen M, Andersen P. Liposome delivery of Chlamydia muridarum major outer membrane protein primes a Th1 response that protects against genital chlamydial infection in a mouse model. J Infect Dis 2008; 198: 758-767.
51. Riber U, Boesen HT, Jakobsen JT, Nguyen LT, Jungersen G. Co-incubation with IL-18 potentiates antigen-specific IFN-gamma response in a whole-blood stimulation assay for measurement of cell-mediated immune responses in pigs experimentally infected with Lawsonia intracellularis. Vet Immunol Immunopathol 2011; 139: 257-263.